Rani Therapeutics Inc.
RANI | NASDAQ
$0.79
$0 (+0.08%)
Sep 22, 2026, 11:20 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 1.63M | 1.03M | n/a | n/a | 2.72M | 462K |
Cost of Revenue | 900K | n/a | 822K | n/a | n/a | n/a |
Gross Profit | 733K | 1.03M | -822K | n/a | 2.72M | 462K |
Operating Income | -38.31M | -53.31M | -66.1M | -63.45M | -51.6M | -16.54M |
Interest Income | 827K | 1.76M | 3.3M | 1.25M | 89K | 63K |
Pretax Income | -40.95M | -30.02M | -67.88M | -63.27M | -53.05M | -16.67M |
Net Income | -29.67M | -30.02M | -33.97M | -30.59M | -8.33M | -16.7M |
Selling & General & Admin | 19.74M | 23.95M | 26.48M | 26.84M | 27.83M | 4.96M |
Research & Development | 20.21M | 26.68M | 39.62M | 36.61M | 26.48M | 12.04M |
Other Expenses | -900K | 3.71M | -822K | n/a | n/a | n/a |
Operating Expenses | 39.04M | 54.34M | 65.28M | 63.45M | 54.32M | 17.01M |
Interest Expense | 2.89M | 5.03M | 5.09M | 1.07M | 466K | 124K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 39.94M | 54.34M | 66.1M | 63.45M | 54.32M | 17.01M |
Income Tax Expense | n/a | 26.57M | n/a | 70K | 41K | 35K |
Shares Outstanding (Basic) | 66.14M | 28.48M | 25.51M | 23.82M | 19.53M | 18.74M |
Shares Outstanding (Diluted) | 66.14M | 28.48M | 25.51M | 23.82M | 19.53M | 18.74M |
EPS (Basic) | -0.45 | -1.05 | -1.33 | -1.28 | -0.42 | -0.85 |
EPS (Diluted) | -0.45 | -1.05 | -1.33 | -1.28 | -0.42 | -0.85 |
EBITDA | -37.16M | -50.52M | -61.98M | -61.66M | -52.08M | -15.96M |
EBIT | -38.06M | -51.55M | -62.8M | -62.2M | -52.58M | -16.54M |
Depreciation & Amortization | 900K | 1.03M | 822K | 548K | 497K | 589K |
Add to Watchlist
Select watchlists to add or remove RANI